The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the ...

Panelists discuss how emerging therapies—including TKIs, sustained-release implants, and gene therapy—may reduce treatment ...

In advanced dry disease, a key problem is failure of retinal pigment epithelium, often shortened to RPE. These cells help ...

Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% ...

Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that dosing is complete in ...